Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Mol Neurosci ; 17: 1362581, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38516041

RESUMO

One of the hallmarks of Alzheimer's disease (AD) is the accumulation of beta-amyloid peptide (Aß) leading to formation of soluble neurotoxic Aß oligomers and insoluble amyloid plaques in various parts of the brain. Aß undergoes post-translational modifications that alter its pathogenic properties. Aß is produced not only in brain, but also in the peripheral tissues. Such Aß, including its post-translationally modified forms, can enter the brain from circulation by binding to RAGE and contribute to the pathology of AD. However, the transport of modified forms of Aß across the blood-brain barrier (BBB) has not been investigated. Here, we used a transwell BBB model as a controlled environment for permeability studies. We found that Aß42 containing isomerized Asp7 residue (iso-Aß42) and Aß42 containing phosphorylated Ser8 residue (pS8-Aß42) crossed the BBB better than unmodified Aß42, which correlated with different contribution of endocytosis mechanisms to the transport of these isoforms. Using microscale thermophoresis, we observed that RAGE binds to iso-Aß42 an order of magnitude weaker than to Aß42. Thus, post-translational modifications of Aß increase the rate of its transport across the BBB and modify the mechanisms of the transport, which may be important for AD pathology and treatment.

2.
Life (Basel) ; 13(1)2023 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-36676097

RESUMO

Phosphorylation of beta-amyloid peptide (Aß) at the Ser8 residue affects its neurotoxicity, metal-dependent oligomerisation, amyloidogenicity, and other pathogenic properties. Phosphorylated Aß (pS8-Aß) was detected in vivo in AD model mice and in the brains of patients with AD. However, the pS8-Aß production and the regulation of its levels have not been previously studied in detail. In this paper, immunochemical methods together with radioactive labelling were used to study the Aß phosphorylation by intracellular and surface protein kinases of HEK293 cells and brain endothelial cells (bEnd.3). It was found that HEK293 robustly phosphorylated Aß, likely with contribution from casein kinase 2 (CK2), whereas in bEnd.3, the activity of Aß phosphorylation was relatively low. Further, the study showed that both HEK293 and bEnd.3 could dephosphorylate pS8-Aß, mainly due to the activity of protein phosphatases PP1 and PP2A. The Aß dephosphorylation efficiency in bEnd.3 was three times higher than in HEK293, which correlated with the reduced abundance of pS8-Aß in vascular amyloid deposits of patients with AD compared to senile plaques. These data suggest an important role of CK2, PP1, and PP2A as regulators of Aß phosphorylation, and point to the involvement of the blood-brain barrier in the control of Aß modification levels.

3.
Int J Mol Sci ; 23(23)2022 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-36499362

RESUMO

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, characterised by the accumulation of senile plaques and tau tangles, neurodegeneration, and neuroinflammation in the brain. The development of AD is a pathological cascade starting according to the amyloid hypothesis with the accumulation and aggregation of the ß-amyloid peptide (Aß), which induces hyperphosphorylation of tau and promotes the pro-inflammatory activation of microglia leading to synaptic loss and, ultimately, neuronal death. Modelling AD-related processes is important for both studying the molecular basis of the disease and the development of novel therapeutics. The replication of these processes is often achieved with the use of a purified Aß peptide. However, Aß preparations obtained from different sources can have strikingly different properties. This review aims to compare the structure and biological effects of Aß oligomers and aggregates of a higher order: synthetic, recombinant, purified from cell culture, or extracted from brain tissue. The authors summarise the applicability of Aß preparations for modelling Aß aggregation, neurotoxicity, cytoskeleton damage, receptor toxicity in vitro and cerebral amyloidosis, synaptic plasticity disruption, and cognitive impairment in vivo and ex vivo. Further, the paper discusses the causes of the reported differences in the effect of Aß obtained from the sources mentioned above. This review points to the importance of the source of Aß for AD modelling and could help researchers to choose the optimal way to model the Aß-induced abnormalities.


Assuntos
Doença de Alzheimer , Peptídeos beta-Amiloides , Humanos , Idoso , Peptídeos beta-Amiloides/metabolismo , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/patologia , Placa Amiloide/patologia , Encéfalo/metabolismo , Desenvolvimento de Medicamentos
4.
Int J Mol Sci ; 24(1)2022 Dec 22.
Artigo em Inglês | MEDLINE | ID: mdl-36613623

RESUMO

The Alzheimer's disease (AD)-associated breakdown of the blood-brain barrier (BBB) promotes the accumulation of beta-amyloid peptide (Aß) in the brain as the BBB cells provide Aß transport from the brain parenchyma to the blood, and vice versa. The breakdown of the BBB during AD may be caused by the emergence of blood-borne Aß pathogenic forms, such as structurally and chemically modified Aß species; their effect on the BBB cells has not yet been studied. Here, we report that the effects of Aß42, Aß42, containing isomerized Asp7 residue (iso-Aß42) or phosphorylated Ser8 residue (p-Aß42) on the mitochondrial potential and respiration are closely related to the redox status changes in the mouse brain endothelial cells bEnd.3. Aß42 and iso-Aß42 cause a significant increase in nitric oxide, reactive oxygen species, glutathione, cytosolic calcium and the mitochondrial potential after 4 h of incubation. P-Aß42 either does not affect or its effect develops after 24 h of incubation. Aß42 and iso-Aß42 activate mitochondrial respiration compared to p-Aß42. The isomerized form promotes a greater cytotoxicity and mitochondrial dysfunction, causing maximum oxidative stress. Thus, Aß42, p-Aß42 and iso-Aß42 isoforms differently affect the BBBs' cell redox parameters, significantly modulating the functioning of the mitochondria. The changes in the level of modified Aß forms can contribute to the BBBs' breakdown during AD.


Assuntos
Doença de Alzheimer , Peptídeos beta-Amiloides , Animais , Camundongos , Peptídeos beta-Amiloides/metabolismo , Barreira Hematoencefálica/metabolismo , Células Endoteliais/metabolismo , Doença de Alzheimer/metabolismo , Oxirredução , Endotélio/metabolismo , Fragmentos de Peptídeos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...